Scottish Medicines Consortium (SMC) Decision Explained Documents to be paused
As the health and care system continues to respond to the impact of the COVID-19 pandemic on services, we face a situation where difficult decisions must be made around where we utilise our resources. In order to deliver the support that the system needs to fully recover, this inevitably means that some work must be paused, rescheduled or redefined.
As a result, we have had to review the resource put into producing the Decision Explained Documents and have had to make the tough decision to temporarily pause their production.
We understand that the Decision Explained Documents, particularly for patient groups and members of the public, offered a more easily understandable version of what can be a complicated process at times. It is regrettable therefore that we feel the need to pause production of this work from October 2022.
We are hopeful that we will be able to reintroduce the documents again in the future.
About us
- Who we are
- Horizon scanning
- Public involvement
- Policies & publications
- Minutes
- Meetings
- Register for a meeting
- ILAP
-
Latest update
- HIS website survey
- Speeding up access to new medicines in Scotland: abbreviated process
- International Collaboration
- Joint statement: NICE and SMC/HIS collaboration
- NICE draft recommendations published on the use of treatments for COVID-19
- Healthcare Improvement Scotland
- NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
- Her Majesty Queen Elizabeth II
- April 2022 decisions news release
- New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
- December 2021 decisions news release
- November 2021 decisions news release
- March 2023 decisions news release
- SMC publishes a Collaborative Advice Document for treatments for COVID-19
- Public Partner Advert
- Fast Track Resubmission Process
- NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
- SMC publishes an updated Collaborative Advice Document for COVID-19 medicines
- NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
- Contact us